Company: ABUS
Filing Date: 2025-03-03
Form Type: 8-K
Source: 0001171843-25-001188
Chunk: 3

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-03
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit Number      Description                                                                                              
            10.1      Agreement, dated March 2, 2025, by and between Arbutus Biopharma Corporation and Genevant Sciences GmbH  
            99.1      Press Release dated March 3, 2025                                                                        
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
             104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                              

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Arbutus Biopharma Corporation                               
  By:                                /s/ David C. Hastings    
                                     David C. Hastings        
                                     Chief Financial Officer